| Literature DB >> 26557651 |
Carline R G van den Breemer1, Marco M M Gresnigt1, Marco S Cune2.
Abstract
AIM: The aim of this comprehensive review is to systematically organize the current knowledge regarding the cementation of glass-ceramic materials and restorations, with an additional focus on the benefits of Immediate Dentin Sealing (IDS).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26557651 PMCID: PMC4628770 DOI: 10.1155/2015/148954
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Assessment of risk of bias of included in vitro ((micro)shear bond strength) studies (n = 17) according to Cochrane collaboration's tool.
| Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? | References |
|---|---|---|---|---|---|---|
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | No | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Yes | No | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | No | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| No | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
Assessment of risk of bias of included in vitro ((micro)tensile bond strength) studies (n = 14) according to Cochrane collaboration's tool.
| Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? | References |
|
| ||||||
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | No | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
Assessment of risk of bias of included in vitro (fracture strength) studies (n = 11) according to Cochrane collaboration's tool.
| Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? | References |
|---|---|---|---|---|---|---|
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| No | NA | NA | Unclear | No | Yes | [ |
| No | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | No | Yes | No | [ |
| Unclear | NA | NA | Unclear | No | No | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
Assessment of risk of bias of included in vitro (marginal gap) studies (n = 26) according to Cochrane collaboration's tool.
| Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? | References |
|---|---|---|---|---|---|---|
| No | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | No | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | Unclear | Yes | [ |
| Unclear | NA | NA | Yes | Unclear | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
| Unclear | NA | NA | No | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Yes | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Unclear | No | Yes | [ |
| Unclear | NA | NA | Unclear | Yes | Yes | [ |
| Unclear | NA | NA | Yes | No | Yes | [ |
| Unclear | NA | NA | Yes | Yes | Yes | [ |
Assessment of risk of bias of included in vivo studies (n = 20) according to Cochrane collaboration's tool.
| Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? | References |
|---|---|---|---|---|---|---|
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | No | Yes | [ |
| No | Unclear | Unclear | No | No | No | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | No | Yes | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | No | No | [ |
| Unclear | Unclear | Unclear | Yes | No | No | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Yes | No | Yes | [ |
| Unclear | Unclear | Unclear | Yes | No | Yes | [ |
| Yes | Unclear | Yes | Yes | Yes | Yes | [ |
| Unclear | Unclear | Unclear | Unclear | No | No | [ |
| Unclear | Unclear | Unclear | Yes | No | Yes | [ |
| Unclear | Unclear | Unclear | Yes | Yes | No | [ |
| Unclear | Yes | Unclear | Yes | Yes | Yes | [ |
| Unclear | Yes | Unclear | Yes | Yes | Yes | [ |
Figure 1Algorithm of study selection procedure.
Figure 2Choices in commonly used resin composite cements.
Cement and adhesive system brand names, manufacturers, city, and countries of origin.
| Cement and adhesive system brand names | Manufacturers | City | Countries of origin |
|---|---|---|---|
| Adapter SingleBond 2 | 3M ESPE | Seefeld | Germany |
| All-bond 2 | Bisco Inc. | Schaumburg, IL | USA |
| Authentic | Ceranay | Stuttgart | Germany |
| Aquacem | Dentsply deTrey | Konstanz | Germany |
| Biomer | Dentsply Caulk | Milford, DE | USA |
| Cavex Clearfil F2 | Cavex | Norden | Germany |
| Cergo | DeguDent | Hanau | Germany |
| Cergogold | DeguDent | Hanau | Germany |
| Chemiace II | Sun Medical | Moriyama City | Japan |
| Clearfil Esthetic Cement | Kuraray | Tokyo | Japan |
| Clearfil Protect Bond | Kuraray | Tokyo | Japan |
| Clearfil SA | Kuraray | Tokyo | Japan |
| DeTrey Zinc | Dentsply deTrey | Konstanz | Germany |
| Definite Multibond primer | DeguDent | Hanau | Germany |
| Definite cement | DeguDent | Hanau | Germany |
| Dicor cement | Dentsply | York, PA | USA |
| Dicor LAC | Dentsply deTrey | Konstanz | Germany |
| Ducere LFC | Ducere | Rosbach | Germany |
| Duo-Link | Bisco Inc. | Schaumburg, IL | USA |
| Dycal | Dentsply Caulk | Milford, DE | USA |
| Dyract-Cem | Dentsply DeTrey | Konstanz | Germany |
| ED primer II | Kuraray | Tokyo | Japan |
| Enforce | Dentsply | São Paulo | Brazil |
| Excite (DSC) | Ivoclar Vivadent | Schaan | Liechtenstein |
| Finesse | Dentsply Ceramco | Burlington, NJ | USA |
| Fleck's | Mizzy Inc. | Cherry Hill | USA |
| Fuji I | GC Corp. | Tokyo | Japan |
| Fuji Plus (F) | GC Corp. | Tokyo | Japan |
| G-Cem | GC Corp. | Tokyo | Japan |
| Geristore | Dent-Mat | Santa Maria | USA |
| GC Fuji Cem | GC Corp. | Tokyo | Japan |
| Go! | 3M ESPE | Seefeld | Germany |
| Harvard | Richter-Hoffman | Berlin | Germany |
| Harvard cement | Harvard Dental | Berlin | Germany |
| iCem | Heraeus Kulzer | Hanau | Germany |
| Illusion Universal Cementation System | Bisco Dental Products | Richmond, BC | Canada |
| IPS E.max Press | Ivoclar Vivadent | Schaan | Liechtenstein |
| IPS Empress (I) (II) | Ivoclar Vivadent | Schaan | Liechtenstein |
| Ketac-Cem | 3M ESPE | St. Paul, MN | USA |
| Linerbond 2V | Kuraray | Osaka | Japan |
| Metabond | Sun Medical | Moriyama City | Japan |
| Maxcem | Kerr-Hawe | Orange, CA | USA |
| Microfil Pontic C | Heraeus Kulzer | Hanau | Germany |
| Mirage | Chameleon Dental | Kansas City, KA | USA |
| Mirage ABC | Chameleon Dental | Kansas City, KA | USA |
| Mirage FLC | Chameleon Dental | Kansas City, KA | USA |
| Multilink (Automix) | Ivoclar Vivadent | Schaan | Liechtenstein |
| Multilink primer | Ivoclar Vivadent | Schaan | Liechtenstein |
| Multilink Sprint | Ivoclar Vivadent | Schaan | Liechtenstein |
| Nexus | Kerr Corp. | Orange, CA | USA |
| Nexus 2 | Kerr Corp. | Orange, CA | USA |
| Nexus 3 | Kerr Corp. | Orange, CA | USA |
| Nexus-high | Kerr Corp. | Orange, CA | USA |
| Noritake Super porcelain | Noritake Dental Supply Co., Ltd. | Nagoya | Japan |
| One Coat Bond | Coltene/Whaledent AG | Altstätten | Switzerland |
| Optibond FL | Kerr Corporation | Orange | United States |
| Panavia 21 | Kuraray | Osaka | Japan |
| Panavia F2.0 | Kuraray | Osaka | Japan |
| Panavia F | Kuraray | Osaka | Japan |
| Protect Liner F | Kuraray | Osaka | Japan |
| Prodigy | Kerr Corp. | Orange, CA | USA |
| RelyX ARC | 3M ESPE | St. Paul, MN | USA |
| RelyX Veneer | 3M ESPE | St. Paul, MN | USA |
| RelyX Unicem (Clicker) | 3M ESPE | St. Paul, MN | USA |
| Single Bond | 3M ESPE | Seefeld | Germany |
| Self-etching primer A+B | Ivoclar Vivadent | Schaan | Liechtenstein |
| SmartCEem 2 | Dentsply Caulk | Milford, DE | USA |
| Spectrum-TPH | Dentsply Caulk | PA | USA |
| SpeedCEM | Ivoclar Vivadent AG | Schaan | Liechtenstein |
| Super-Bond C&B | Sun Medical | Moriyama City | Japan |
| Super porcelain EX-3 | Noritake Kizai Co. | Nagoya | Japan |
| Syntac (classic) | Ivoclar Vivadent | Schaan | Liechtenstein |
| Temp Bond | Kerr | Corporation, Orange | United States |
| Tetric flow | Ivoclar Vivadent | Schaan | Liechtenstein |
| Universal glass ionomer | Super Dent | Westbury, NY | USA |
| Variolink II | Ivoclar Vivadent | Schaan | Liechtenstein |
| Variolink II base | Ivoclar Vivadent | Schaan | Liechtenstein |
| Variolink II refill | Ivoclar Vivadent | Schaan | Liechtenstein |
| Variolink II Ultra | Ivoclar Vivadent | Schaan | Liechtenstein |
| Vitadur Alpha | Vita | Bad Säckingen | Germany |
| Vita Cerec Duo Cement | Coltene/Whaledent AG | Altstätten | Switzerland |
| Vita Mark II | Vita | Bad Säckingen | Germany |